25 February 2021  
EMA/CHMP/111163/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Sarclisa 
isatuximab 
On 25 February 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Sarclisa. The marketing authorisation holder for this medicinal product is sanofi-aventis groupe. 
The CHMP adopted an extension to the existing indication as follows:2  
Sarclisa is indicated: 
- in combination with pomalidomide and dexamethasone, for the treatment of adult patients 
with relapsed and refractory multiple myeloma who have received at least two prior therapies 
including lenalidomide and a proteasome inhibitor and have demonstrated disease progression 
on the last therapy. 
- in combination with carfilzomib and dexamethasone, for the treatment of adult 
patients with multiple myeloma who have received at least one prior therapy (see 
section 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
